Market News & Trends
Starton Therapeutics Announces Approval to Proceed With Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD
Starton Therapeutics Inc. recently announced the Independent Data Monitoring Committee reviewed the totality of the safety data from the first two cohorts and recommended advancement…
Recce Pharmaceuticals Announces Positive Safety Data From Fifth Cohort of Phase 1 Clinical Trial
Recce Pharmaceuticals Ltd. recently announced that in cohort five of a Phase 1 clinical trial, R327 demonstrated a good safety and tolerability profile among 10…
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study With Tovorafenib & Pimasertib in RAF-Altered Solid Tumors
Day One Biopharmaceuticals recently announced the first patients have been dosed in sub-study 2 of FIRELIGHT-1, a Phase 1b/2 clinical trial evaluating tovorafenib (DAY101) in…
Innoviva to Acquire Entasis Therapeutics
Innoviva, Inc. and Entasis Therapeutics Holdings Inc. recently announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all….
Ajinomoto Licenses Genedata Bioprocess for Development of High-Performance Cell Culture Media
Genedata recently announced Ajinomoto has deployed Genedata Bioprocess to digitalize and automate their R&D and manufacturing operations in Japan and Korea…..
N4 Pharma Highlights Potential of Nuvec as Gene Therapy Delivery Platform
A recent preclinical in-vivo study found that Nuvec – N4 Pharma’s novel silica-based nanoparticle – formulated with TNF-α pDNA oncotherapy, suppressed tumor growth and improved survival of….
Catalent Invests $175 Million to Expand Manufacturing Capabilities & Capacity
Catalent recently announced that it has commenced a $175 million project to expand its flagship US manufacturing facility for large scale oral dose forms in…
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients With p53-Mutated Neoadjuvant Breast Cancer
Aileron Therapeutics recently announced it has treated the first patients in its Phase 1b randomized, controlled clinical trial evaluating ALRN-6924 to protect against chemotherapy-induced neutropenia…
Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3
Biomea Fusion, Inc. recently announced the nomination of its second product candidate, BMF-500, a highly selective and potent covalent investigational third-generation….
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
Caladrius Biosciences, Inc. recently announced the Independent Data Monitoring Committee (IDMC) overseeing the Phase 1b, open-label, proof-of-concept study of CLBS201 for the treatment of diabetic kidney disease (DKD) has reviewed the initial safety….
Rafael Pharmaceuticals Announces Corporate Name Change to Cornerstone Pharmaceuticals
Rafael Pharmaceuticals, Inc. recently announced it is changing its name to Cornerstone Pharmaceuticals, Inc., its original company name. All company branding, including the website and…
Headlands Research & Pfizer Partnership to Significantly Improve Diversity in Clinical Trials
Headlands Research recently announced a partnership with Pfizer Inc. to launch new research sites in areas with highly diverse populations, further advancing Headlands’ mission to…
Croda Announces the New Pharma Business
Croda recently announced that its Health Care division will now become Croda Pharma, bringing its core speciality excipient portfolio together with the recent acquisition, Avanti Polar Lipids and its….
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO (Testosterone Undecanoate)
Clarus Therapeutics Holdings, Inc. recently announced that the United States Patent and Trademark Office (USPTO) has issued a new patent for claims that cover Clarus’ oral testosterone replacement product….
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma
Avalo Therapeutics, Inc. recently announced the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group…
Lilly Receives MHRA Marketing Authorisation for Abemaciclib in Combination With Endocrine Therapy for Adjuvant Treatment of People With HR+, HER2- High-Risk Early Breast Cancer
Eli Lilly and Company recently announced the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for abemaciclib in combination with endocrine…
Vetter Achieves a Three-Peat in Winning the Best Managed Companies Award
For the third year in a row, Vetter has won the Best Managed Companies Award. With this three-win feat, the pharmaceutical service provider has once again…
4D pharma Presents Late-Breaking Abstract From Phase 1/2 Trial of MRx-4DP0004 for the Treatment of Asthma
4D pharma plc recently announced the presentation of a late-breaking poster on data from Part A of the Phase 1/2 trial of MRx-4DP0004 for the…
MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma
MannKind Corporation recently announced it has entered into an agreement with Zealand Pharma A/S to acquire V-Go for $10 million, with additional sales-based milestones plus the cost of certain….
IN8bio Announces Data Emerging From its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
IN8bio, Inc. recently announced data emerging from the company’s recently unveiled iPSC-based gamma-delta T cell platform. iPSCs represent a significant step toward next generation approaches…
